PAK1 and melanoma: Overall, ample evidence suggests that PAK1 by itself is a critical vulnerability in a sizeable subset of melanomas, while its co-targeting has the potential to enhance MAPK-directed targeted therapies and circumvent many common modes of resistance to the latter.